Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporti

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice Department. Regeneron allegedly inflated the sales price of it

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value o

TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursda

Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, w

Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.

As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performanc

Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite

A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu

The Investment Committee debate the latest calls of the day on a number of stocks.

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)